Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10
Journal Article
Overview
publication date
has subject area
-
Adenoviridae
-
Animals
-
Antigens, Surface - Receptors, Interleukin-1 Type I
-
Behavior, Animal
-
Biological Factors - Interleukin-1
-
Biological Factors - Interleukin-1
-
Biological Factors - Interleukin-10
-
Biological Therapy - Genetic Therapy
-
Biomarkers - Receptors, Interleukin-1 Type I
-
Disease Management - Pain Management
-
Genetic Engineering - Genetic Therapy
-
Genetic Vectors
-
Hindlimb
-
Humans
-
Injections - Microinjections
-
Injections, Spinal
-
Male
-
Micromanipulation - Microinjections
-
Nervous System Diseases - Pain
-
Nervous System Physiological Phenomena - Functional Laterality
-
Nervous System Physiological Phenomena - Pain
-
Nervous System Physiological Phenomena - Pain Threshold
-
Pain Measurement
-
Peptides - Interleukin-1
-
Peptides - Interleukin-1
-
Peptides - Interleukin-10
-
Pharmacological Phenomena - Dose-Response Relationship, Drug
-
Proteins - Interleukin-1
-
Proteins - Interleukin-1
-
Proteins - Interleukin-10
-
Psychological Phenomena and Processes - Functional Laterality
-
Psychological Phenomena and Processes - Pain
-
Psychological Phenomena and Processes - Pain Threshold
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Interleukin-1
-
Receptors, Interleukin-1 - Receptors, Interleukin-1 Type I
-
Sensory Thresholds - Pain Threshold
-
Signs and Symptoms - Pain
-
Therapeutics - Pain Management
-
Time Factors
-
Toxicological Phenomena - Dose-Response Relationship, Drug
-
Zymosan
Full Author List
-
Milligan ED; Langer SJ; Sloane EM; He L; Wieseler-Frank J; O'Connor K; Martin D; Forsayeth JR; Maier SF; Johnson K
published in
Other Profiles
Digital Object Identifier (DOI)
Additional Document Info
start page
end page
volume
issue